drugset
Drugs / Rivoceranib
last change 10 days ago re-read 8 days ago

Rivoceranib

also known as apatinib · Apatinib mesylate · Apatinib-Mesylate Tablets · YN968D1 · Aitan · Apatinib (Apatinib Mesylate Tablets, Jiangsu Hengrui Medicine, China) · Apatinib (registered name in China) · Apatinib free base · +6 more

Small molecule targets KDR, KIT, RET, SRC via inhibition

Developed for
hepatocellular carcinoma · gastric cancer · non-small cell lung carcinoma · small cell lung carcinoma · colorectal cancer · triple-negative breast carcinoma · breast cancer · esophageal squamous cell carcinoma
+107 more · gastric adenocarcinoma · ovarian cancer · gastroesophageal junction adenocarcinoma · nasopharyngeal carcinoma · esophageal cancer · biliary tract cancer · gastroesophageal adenocarcinoma · intrahepatic cholangiocarcinoma · cancer · gastric carcinoma · head and neck squamous cell carcinoma · osteosarcoma · sarcoma · soft tissue sarcoma · Her2-receptor negative breast cancer · lung cancer · melanoma · hormone receptor-positive breast cancer · malignant pancreatic neoplasm · neoplasm · adenoid cystic carcinoma · cervical cancer · cervical carcinoma · cholangiocarcinoma · differentiated thyroid carcinoma · digestive system cancer · female breast carcinoma · gastroesophageal cancer · lung adenocarcinoma · metastatic neoplasm · ovarian carcinoma · thyroid cancer · adrenal cortex carcinoma · cancer of unknown primary site · carcinoma of esophagus · colorectal neoplasm · digestive system carcinoma · fallopian tube cancer · gastrointestinal stromal tumor · gestational trophoblastic neoplasm · glioma · head and neck cancer · head and neck neoplasm · liver cancer · malignant glioma · metastatic carcinoma · mucosal melanoma · peripheral T-cell lymphoma, not otherwise specified · primary peritoneal carcinoma · acral lentiginous melanoma · adenocarcinoma · adult hepatocellular carcinoma · ALK-positive anaplastic large cell lymphoma · bile duct carcinoma · biliary tract neoplasm · carcinoma · carcinosarcoma · chordoma · colon carcinoma · combined hepatocellular carcinoma and cholangiocarcinoma · connective and soft tissue neoplasm · dedifferentiated liposarcoma · diffuse large B-cell lymphoma · endometrial cancer · extranodal nasal NK/T cell lymphoma · gallbladder carcinoma · high grade astrocytic tumor · high grade B-cell lymphoma · lung carcinoma · lung neoplasm · malignant epithelial tumor of ovary · medulloblastoma · meningioma · metastasis from malignant tumor of colon · metastatic malignant neoplasm · metastatic malignant neoplasm in the brain · metastatic prostate carcinoma · nasopharyngeal neoplasm · neoplasm of esophagus · neuroblastoma · neuroendocrine carcinoma · neuroendocrine neoplasm · olfactory neuroblastoma · oral cavity cancer · oral cavity squamous cell carcinoma · ovarian serous adenocarcinoma · pancreatic ductal adenocarcinoma · pancreatic exocrine neoplasm · pancreatic neoplasm · peritoneal carcinomatosis · peritoneal neoplasm · radiation-induced disorder · rectal cancer · refractory malignant neoplasm · renal cell carcinoma · rhabdomyosarcoma · salivary gland carcinoma · sarcomatoid carcinoma · squamous cell lung carcinoma · T-cell and NK-cell neoplasm · thymic epithelial neoplasm · thyroid gland carcinoma · thyroid gland disorder · urothelial carcinoma · uterine cancer · cutaneous melanoma · peritoneal mesothelioma
Investigated by
Jiangsu HengRui Medicine Co., Ltd. · Sun Yat-sen University · Fudan University · Tianjin Medical University Cancer Institute and Hospital · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Fujian Cancer Hospital
+248 more · Henan Cancer Hospital · Peking University Cancer Hospital & Institute · Peking Union Medical College Hospital · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Chinese Academy of Medical Sciences · Elevar Therapeutics · Hebei Medical University Fourth Hospital · Peking University People's Hospital · The First Affiliated Hospital of Zhengzhou University · Jiangsu Hengrui Pharmaceutical Co., Ltd. · West China Hospital · Zhejiang Cancer Hospital · Peking University · Shanghai Zhongshan Hospital · Beijing Friendship Hospital · Chinese PLA General Hospital · Hebei Medical University · Ruijin Hospital · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Sichuan Cancer Hospital and Research Institute · The First Hospital of Jilin University · Anhui Provincial Hospital · First Affiliated Hospital Xi'an Jiaotong University · Liaoning Cancer Hospital & Institute · Second Affiliated Hospital, School of Medicine, Zhejiang University · The First Affiliated Hospital of Xiamen University · The First Affiliated Hospital with Nanjing Medical University · Beijing Chest Hospital · China Medical University, China · Fujian Medical University · Peking University Shougang Hospital · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Zhejiang University · Guangxi Medical University · Guangxi Naxishan Hospital · Huazhong University of Science and Technology · Hubei Cancer Hospital · Hunan Cancer Hospital · Nanfang Hospital, Southern Medical University · Peking University Third Hospital · Qilu Hospital of Shandong University · Shandong Cancer Hospital and Institute · Shenzhen People's Hospital · The First Affiliated Hospital of Bengbu Medical University · Third Military Medical University · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuzhou Red Cross Hospital · Xinqiao Hospital of Chongqing · Zhongshan Hospital Xiamen University · Affiliated Hospital of Guangdong Medical University · Affiliated Hospital of Nantong University · Affiliated Hospital of North Sichuan Medical College · Anhui Provincial Cancer Hospital · Beijing Hospital · Beijing Sanbo Brain Hospital · Beijing Tsinghua Chang Gung Hospital · Bukwang Pharmaceutical · Chinese Society of Clinical Oncology · Chongqing University Cancer Hospital · Eastern Hepatobiliary Surgery Hospital · First Affiliated Hospital of Guangxi Medical University · First Affiliated Hospital of Zhejiang University · First Hospital of China Medical University · First People's Hospital of Foshan · Fujian Medical University Union Hospital · Fuzhou General Hospital · Guangdong Provincial People's Hospital · Guangzhou Virotech Pharmaceutical Co., Ltd. · Guilin Medical University, China · Harbin Medical University · Huangshi Central Hospital · Huashan Hospital · Jiangsu Hansoh Pharmaceutical Co., Ltd. · Jiuda Zhao · all 254 on the full record

Trials 532 · started per year

today
1
1
3
4
1
1
16
51
76
63
61
64
46
28
25
42
31
18
2007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT04074564 Nov 2019 → Aug 2024 sarcoma HRYZ Biotech Co. Unknown No outcome recorded
Phase 133 trials · 1 met primary
Phase 1 NCT06769425 May 2025 → May 2026 overdue female breast carcinoma, gastric cancer, ovarian cancer, prostate cancer +1 Jiangsu Hansoh Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 1 NCT06181032 Dec 2023 → Feb 2029 expected biliary tract cancer First Affiliated Hospital of Fujian Medical University Recruiting No outcome recorded
Phase 1 NCT05287360 Dec 2021 → Mar 2022 — Elevar Therapeutics Completed No outcome recorded
Phase 1 NCT05001412 Jan 2021 → Jan 2023 small cell lung carcinoma Zhou Chengzhi Unknown No outcome recorded
Phase 1 NCT04665362 Jan 2021 → Jun 2022 hepatocellular carcinoma Liang Peng Unknown No outcome recorded
Phase 1 NCT04457180 Nov 2020 → May 2021 — Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT04428086 Jul 2020 → Aug 2021 cancer Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT04414852 Jun 2020 → Jan 2021 — Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 1 NCT04390984 May 2020 → Feb 2021 non-small cell lung carcinoma Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 1 NCT04341090 May → Jul 2020 — Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 1/232 trials
Phase 1/2 NCT07802184 Sep 2026 → Jan 2029 expected pancreatic ductal adenocarcinoma West China Hospital Not yet recruiting No outcome recorded
Phase 1/2 NCT07479732 Mar 2026 → Mar 2027 expected osteosarcoma Peking University People's Hospital Recruiting No outcome recorded
Phase 1/2 NCT06592287 Sep 2024 → Sep 2025 overdue gastric cancer Xianglin Yuan Not yet recruiting No outcome recorded
Phase 1/2 NCT06607770 Sep 2024 → Aug 2026 overdue lung cancer Zhou Chengzhi Recruiting No outcome recorded
Phase 1/2 NCT05924997 Jul 2023 → Jun 2025 hepatocellular carcinoma Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Unknown No outcome recorded
Phase 1/2 NCT05742750 Apr 2023 → Dec 2025 biliary tract cancer Sun Yat-sen University Completed No outcome recorded
Phase 1/2 NCT05559008 Sep 2022 → Mar 2024 peripheral T-cell lymphoma, not otherwise specified Ruijin Hospital Unknown No outcome recorded
Phase 1/2 NCT05019690 Oct 2021 → Dec 2024 overdue triple-negative breast carcinoma Fujian Cancer Hospital Recruiting No outcome recorded
Phase 1/2 NCT05027386 Aug 2021 → Feb 2026 neuroblastoma Sun Yat-sen University Completed No outcome recorded
Phase 1/2 NCT04476459 Jul 2020 → Aug 2022 ALK-positive anaplastic large cell lymphoma, high grade B-cell lymphoma Huiqiang Huang Unknown No outcome recorded
Phase 2368 trials · 7 met primary · 3 missed
Phase 2 NCT07684040 Aug 2026 → Jul 2030 expected liver cancer Affiliated Hospital of Guangdong Medical University Not yet recruiting No outcome recorded
Phase 2 NCT07687433 May 2026 → May 2028 expected rectal cancer Harbin Medical University Active not recruiting No outcome recorded
Phase 2 NCT07610629 May 2026 → Dec 2028 expected gastric adenocarcinoma Henan Cancer Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07463248 Apr 2026 → Jan 2028 expected hepatocellular carcinoma Wang Xin Recruiting No outcome recorded
Phase 2 NCT07464756 Apr 2026 → May 2028 expected gastric adenocarcinoma The First Affiliated Hospital with Nanjing Medical University Recruiting No outcome recorded
Phase 2 NCT07314372 Feb 2026 → Dec 2027 expected adult hepatocellular carcinoma The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Not yet recruiting No outcome recorded
Phase 2 NCT07333287 Feb 2026 → Feb 2027 expected digestive system carcinoma Shandong Provincial Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07357532 Jan 2026 → Sep 2028 expected small cell lung carcinoma Peking University Cancer Hospital & Institute Not yet recruiting No outcome recorded
Phase 2 NCT07363356 Jan → Oct 2026 expected hepatocellular carcinoma Eastern Hepatobiliary Surgery Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07311408 Jan 2026 → Jan 2028 expected gastric cancer, gastroesophageal junction adenocarcinoma Jingdong Zhang Recruiting No outcome recorded
Show all 368 trials opens the full record — a long page
Phase 2/318 trials · 1 met primary
Phase 2/3 NCT07653451 Jul 2026 → Dec 2027 expected esophageal squamous cell carcinoma Peking University Cancer Hospital & Institute Not yet recruiting No outcome recorded
Phase 2/3 NCT07589244 May 2026 → Dec 2028 expected hepatocellular carcinoma Guangzhou Virotech Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 2/3 NCT06739317 Jan 2025 → Dec 2030 expected hepatocellular carcinoma Sun Yat-sen University Not yet recruiting No outcome recorded
Phase 2/3 NCT05699655 May 2023 → Mar 2025 overdue — Fujian Cancer Hospital Recruiting No outcome recorded
Phase 2/3 NCT04968002 Aug 2021 → Aug 2022 non-small cell lung carcinoma Second Affiliated Hospital, School of Medicine, Zhejiang University Unknown No outcome recorded
Phase 2/3 NCT05062837 Jun 2021 → Dec 2026 expected hepatocellular carcinoma Guangxi Medical University Recruiting No outcome recorded
Phase 2/3 NCT04803539 Apr 2021 → Sep 2028 expected breast cancer Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting No outcome recorded
Phase 2/3 NCT04521153 Mar 2021 → Jul 2025 overdue hepatocellular carcinoma Shanghai Zhongshan Hospital Active not recruiting Met primary
Phase 2/3 NCT04208347 Dec 2019 → Dec 2026 expected gastroesophageal adenocarcinoma Ruijin Hospital Active not recruiting No outcome recorded
Phase 2/3 NCT03580395 Jun 2017 → Jul 2022 breast cancer Hebei Medical University Fourth Hospital Unknown No outcome recorded
Phase 343 trials · 6 met primary
Phase 3 NCT07314203 Dec 2026 → Aug 2027 expected gastric cancer Fujian Medical University Not yet recruiting No outcome recorded
Phase 3 NCT06925243 Apr 2025 → Dec 2027 expected gastroesophageal adenocarcinoma Zuoyi Jiao Recruiting No outcome recorded
Phase 3 NCT06913777 Apr 2025 → Oct 2026 expected — Fudan University Recruiting No outcome recorded
Phase 3 NCT06889688 Feb 2025 → Dec 2028 expected triple-negative breast carcinoma Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting No outcome recorded
Phase 3 NCT06188455 Dec 2024 → Dec 2025 overdue ovarian cancer The First Affiliated Hospital of Xiamen University Not yet recruiting No outcome recorded
Phase 3 NCT06539091 Oct 2024 → Oct 2025 overdue malignant epithelial tumor of ovary Anhui Provincial Hospital Not yet recruiting No outcome recorded
Phase 3 NCT07371910 Jun 2024 → Mar 2031 expected Her2-receptor negative breast cancer Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Active not recruiting No outcome recorded
Phase 3 NCT06255392 Jun 2024 → Mar 2031 expected Her2-receptor negative breast cancer Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting No outcome recorded
Phase 3 NCT06447623 Jun 2024 → Feb 2027 expected hormone receptor-positive breast cancer Fudan University Active not recruiting No outcome recorded
Phase 3 NCT06438627 May 2024 → May 2026 overdue nasopharyngeal carcinoma XIANG YANQUN Recruiting No outcome recorded
Phase 49 trials
Phase 4 NCT05029453 Aug 2021 → Dec 2022 gastric cancer Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Unknown No outcome recorded
Phase 4 NCT03792503 Feb 2019 → Feb 2020 non-small cell lung carcinoma Xinqiao Hospital of Chongqing Withdrawn No outcome recorded
Phase 4 NCT03725423 Oct 2018 → Jun 2019 squamous cell lung carcinoma Xuzhou Central Hospital Unknown No outcome recorded
Phase 4 NCT03631862 Sep 2018 → Dec 2019 peripheral T-cell lymphoma, not otherwise specified Zhengzhou University Unknown No outcome recorded
Phase 4 NCT03475589 Feb 2018 → Dec 2020 — Sun Yat-sen University Unknown No outcome recorded
Phase 4 NCT03376958 Jan 2017 → Feb 2019 diffuse large B-cell lymphoma Zhengzhou University Completed No outcome recorded
Phase 4 NCT03384511 Sep 2016 → Jan 2018 breast cancer, cervical cancer, esophageal cancer, gastric cancer +2 Shandong Cancer Hospital and Institute Completed No outcome recorded
Phase 4 NCT02776527 Apr 2016 → Apr 2017 gastric cancer Tianjin Medical University Cancer Institute and Hospital Unknown No outcome recorded
Phase 4 NCT02426034 May 2015 → May 2020 gastroesophageal adenocarcinoma Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase not applicable28 trials · 1 met primary
— NCT07618546 May 2026 → Mar 2027 expected hepatocellular carcinoma Henan Cancer Hospital Not yet recruiting No outcome recorded
— NCT07371871 Jan 2026 → Dec 2027 expected gastric cancer Anhui Provincial Cancer Hospital Not yet recruiting No outcome recorded
— NCT06893887 May 2025 → Dec 2027 expected hepatocellular carcinoma Nanjing Tianyinshan Hospital Recruiting No outcome recorded
— NCT06480864 Aug 2024 → Aug 2025 overdue small cell lung carcinoma Yunpeng Liu Recruiting No outcome recorded
— NCT06102707 Nov 2023 → Nov 2025 overdue ovarian carcinoma Qilu Hospital of Shandong University Not yet recruiting No outcome recorded
— NCT05751733 Feb 2023 → Jan 2026 overdue gastrointestinal stromal tumor Xiangya Hospital of Central South University Recruiting No outcome recorded
— NCT05653817 Jan 2023 → Jan 2025 cholangiocarcinoma First Affiliated Hospital Xi'an Jiaotong University Unknown No outcome recorded
— NCT05380986 May 2022 → May 2024 cancer Henan Cancer Hospital Unknown No outcome recorded
— NCT04950400 Jul 2021 → Dec 2023 non-small cell lung carcinoma Beijing Chest Hospital Unknown No outcome recorded
— NCT04690231 Dec 2020 → Mar 2021 poisoning Peking University People's Hospital Completed No outcome recorded
Comparator or background therapy25 trials
Phase 1/2 NCT04581473 Comparator Oct 2020 → Oct 2024 overdue gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, malignant pancreatic neoplasm CARsgen Therapeutics Co., Ltd. Active not recruiting Met primary
Phase 2 NCT07793695 Background Sep 2026 → Aug 2027 expected hepatocellular carcinoma Anhui Provincial Hospital Recruiting No outcome recorded
Phase 2 NCT07691645 Background Sep 2026 → Aug 2029 expected hepatocellular carcinoma Xiang-Qian Not yet recruiting No outcome recorded
Phase 2 NCT07682272 Background Jul 2026 → Jul 2027 expected hepatocellular carcinoma Suzhou Suncadia Biopharmaceuticals Co., Ltd. Not yet recruiting No outcome recorded
Phase 2 NCT06339281 Comparator May 2024 → Jun 2026 overdue breast cancer Li Huiping Not yet recruiting No outcome recorded

Evidence & citations 19 cited values

Every value below carries the sentence it was read from. 561 sources stand behind the page.

FieldValueCited text
Known as rivoceranib “A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in...” PMID 36797744 ↗ Feb 2023
17

“Apatinib \[Aitan® (brand name in China)\], also known as rivoceranib, is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine...” NCT04878107 ↗

“Apatinib [Aitan® (brand name in China)], also known as rivoceranib, is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine...” PMID 29663291 ↗ May 2018

NCT05287360 ↗

NCT07311408 ↗

NCT04073615 ↗

NCT07684040 ↗

NCT04985136 ↗

NCT03707028 ↗

NCT03042611 ↗

NCT07105748 ↗

Show 7 more sources
Known as Aitan “Apatinib \[Aitan® (brand name in China)\], also known as rivoceranib, is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine...” NCT04878107 ↗
1

“Apatinib [Aitan® (brand name in China)], also known as rivoceranib, is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine...” PMID 29663291 ↗ May 2018
Known as apatinib “Drug sensitivity testing will be performed on a panel of approved targeted and immunotherapeutic agents (including Apatinib, Atezolizumab + Bevacizumab, Donafenib +...” NCT07363356 ↗
538

“The first-line targeted-immunotherapy regimens consisted of tislelizumab combined with one of the first-line evidence-based tyrosine kinase inhibitors (TKIs), including...” NCT07463248 ↗

“Treatment period: Therapeutic agents were selected according to clinical routine, including but not limited to Sorafenib, Lenvatinib, Donafenib, Regorafenib, Apatinib and Cabozantinib.” NCT05673824 ↗

“This phase II trial (NCT04318730) evaluated the efficacy and safety of the PD-1 inhibitor camrelizumab combined with the VEGFR inhibitor apatinib in previously treated advanced ACC.” PMID 39609453 ↗ Nov 2024

“Patients received 2-3 cycles of neoadjuvant therapy with camrelizumab, nedaplatin, albumin paclitaxel, and apatinib; each cycle was repeated every 14 days.” PMID 38618203 ↗ Apr 2024

“Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally on the 1st day 30minutes after meals, once a day, for continuous medication.” NCT05099848 ↗

“Apatinib: 250mg orally, QD, 5 days of medication, 2 days off (5 on 2 off) or once every other day (QOD), half an hour after meals” NCT06320301 ↗

“All participants will receive neoadjuvant therapy with combination of Camrelizumab、Apatinib and Temozolomide for 2 cycle；” NCT05512481 ↗

“Apatinib 250 mg twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days;” NCT05216237 ↗

“Apatinib mesylate tablets: The initial dose is 250 mg, administered once a day, and continue to be administered.” NCT04507750 ↗

“Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE Natural Killer /T-cell Lymphoma” NCT04366128 ↗

Show 528 more sources
Known as Apatinib (Apatinib Mesylate Tablets, Jiangsu Hengrui Medicine, China) “Apatinib (Apatinib Mesylate Tablets, Jiangsu Hengrui Medicine, China)” NCT05742750 ↗
Known as Apatinib (registered name in China) ChEMBL registry synonym — accepted as the source's own label CHEMBL3186534 ↗
Known as Apatinib free base ChEMBL registry synonym — accepted as the source's own label CHEMBL3186534 ↗
Known as Apatinib mesylate “Apatinib mesylate tablet is an oral small molecule tyrosine kinase inhibitor (TKI), which can specifically bind to vascular endothelial growth factor receptor 2 (VEGFR-2) and...” NCT04152681 ↗
42

“Apatinib mesylate: a small molecule of tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) , 250mg, once daily, to be swallowed with...” NCT06759090 ↗

“Apatinib Mesylate (Etan) is a new type of small molecule anti-angiogenic agent, which is a small molecule TKI against VEGFR2 independently developed in China and has the effect...” NCT05751733 ↗

“apatinib Mesylate is a small molecule tyrosine kinase inhibitor,Through selectively inhibiting the tyrosine kinase activity of the vascular endothelial growth factor receptor 2...” NCT04397770 ↗

“Apatinib mesylate tablets: Orally, 500 mg, once a day, with warm water for half an hour after a meal (the time of taking the medicine every day should be the same as possible).” NCT04501705 ↗

“Apatinib mesylate: 250mg, qd, stopped 28 days before surgery, and can be used by the investigator according to the patient's recovery 28 days after surgery.” NCT04792515 ↗

“During the treatment period, 250 mg of Apatinib mesylate tablets will be taken orally daily continuously, and every 2 weeks is a treatment cycle.” NCT05342389 ↗

“Apatinib mesylate is a highly selective small-molecule vasoendothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor.” NCT05027386 ↗

“Apatinib mesylate will be administered 250mg or 500mg (according to the patient's tolerance), qd, oral, until disease progression.” NCT04006821 ↗

“Apatinib mesylate is a new inhibitor of VEGFR-2 tyrosine kinase targeting the intracellular ATPbinding site of the receptor.” NCT03651219 ↗

“Apatinib mesylate is a small molecule VEGFR tyrosine kinase inhibitor authored by Jiangsu Hengrui Pharmaceutical Co., Ltd.” NCT03393507 ↗

Show 32 more sources
Known as Apatinib Tablets “Apatinib Tablets, recommended dose of 850mg” NCT02426034 ↗
Known as Apatinib-Mesylate Tablets “Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally 30minutes after meals, once a day, for continuous medication” NCT05313282 ↗
6

“Apatinib Mesylate Tablets 500 mg qd p.o.” NCT02509806 ↗

“Apatinib Mesylate Tablets：250mg，P.O，qod” NCT06614621 ↗

“Drug: Apatinib Mesylate Tablets” NCT02836821 ↗

“Drug: Apatinib mesylate tablets” NCT03219593 ↗

“Drug: Apatinib Mesylate Tablets” NCT06188455 ↗

“apatinib mesylate tablets” NCT03064243 ↗
Known as Etan “Apatinib Mesylate (Etan) is a new type of small molecule anti-angiogenic agent, which is a small molecule TKI against VEGFR2 independently developed in China and has the effect...” NCT05751733 ↗
Known as mesylate apatinib “mesylate apatinib, 250 mg, oral once a day, continuous oral” NCT04834674 ↗
Known as Methylsulfonic apatinib “Methylsulfonic apatinib is one of those TKIs which specifically inhibits VEGFR-2.” NCT03491371 ↗
Known as rivoceranib mesylate “Rivoceranib mesylate (750 mg, QD, po)” NCT04985136 ↗
Known as YN968D1 “Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR).” NCT03390062 ↗
3

“BACKGROUND: YN968D1 (Apatinib) selectively inhibits phosphorylation of VEGFR-2 and tumor angiogenesis in mice model.” PMID 20923544 ↗ Oct 2010

“Apatinib(YN968D1) ,850mg,p.o.,qd,continuous.” NCT02493582 ↗

NCT01497704 ↗
Known as YN968D1 FREE BASE ChEMBL registry synonym — accepted as the source's own label CHEMBL3186534 ↗
Action Inhibit “YN968D1 (Apatinib) selectively inhibits phosphorylation of VEGFR-2 and tumor angiogenesis in mice model.” PMID 20923544 ↗ Oct 2010
Modality Small molecule “It is an orally bioavailable, small molecule agent” NCT02515435 ↗
Route Oral “orally administered apatinib” PMID 20923544 ↗ Oct 2010
Target RET “Apatinib is an oral multi-kinase inhibitors including RET fusions.” NCT02540824 ↗